Comparative Pharmacology
Head-to-head clinical analysis: BELRAPZO versus DACARBAZINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BELRAPZO versus DACARBAZINE.
BELRAPZO vs DACARBAZINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
BELRAPZO (bendamustine hydrochloride) is a bifunctional mechlorethamine derivative that alkylates and crosslinks DNA, leading to cell death. It also exhibits purine analog-like properties, inhibiting DNA synthesis and repair.
Alkylating agent; inhibits DNA and RNA synthesis by forming covalent bonds with DNA, leading to cross-linking and strand breaks. Also inhibits purine synthesis and has some activity as a methylating agent.
260 mg/m2 intravenously every 21 days.
2.4-4.5 mg/kg IV daily for 10 days every 28 days; or 250 mg/m2 IV daily for 5 days every 21 days; or 375-450 mg/m2 IV single dose every 21-28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 1-2 minutes (rapid plasma clearance due to carboxylesterase-mediated hydrolysis).
Clinical Note
moderateDacarbazine + Digoxin
"Dacarbazine may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDacarbazine + Digitoxin
"Dacarbazine may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDacarbazine + Deslanoside
"Dacarbazine may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDacarbazine + Acetyldigitoxin
"Dacarbazine may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal half-life: 5 hours (range 3-8 h) after IV administration; biphasic decay with initial half-life ~19 min.
Primarily renal excretion: ~70-80% of administered dose excreted unchanged in urine; minor biliary/fecal elimination (<5%).
Renal: 40-50% unchanged; hepatic: 30-50% as metabolites (primarily 5-aminoimidazole-4-carboxamide); <10% fecal.
Category C
Category D/X
Alkylating Agent
Alkylating Agent